Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors

著录项

• 来源
  《Investigational New Drugs》 |2015年第2期|450-462|共13页
• 作者

  C. S. Higano; J. Berlin; M. Gordon; P. LoRusso; S. Tang; A. Dontabhaktuni; J. D. Schwartz; J. Cosaert; J. M. Mehnert;

  展开▼
• 作者单位

  Departments of Medicine and Urology University of Washington and Fred Hutchinson Cancer Research Center">(1);

  University of Washington Seattle Cancer Care Alliance">(9);

  Vanderbilt Ingram Cancer Center Vanderbilt University">(2);

  Pinnacle Oncology Hematology">(3);

  Karmanos Cancer Institute Wayne State University">(4);

  Yale Cancer Center">(7);

  Eli Lilly and Company">(5);

  Eli Lilly and Company">(5);

  Eli Lilly and Company">(5);

  Stemline Therapeutics Inc.">(8);

  Eli Lilly and Company">(5);

  Rutgers Cancer Institute of New Jersey">(6);

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类
• 关键词

  IGF-IR; Cixutumumab; IMC-A12; Phase I; Dose schedule;

  机译：IGF-IR;西妥单抗;IMC-A12;第一阶段;剂量表;